0M61 Stock Overview A wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Myomo Historical stock prices Current Share Price US$5.65 52 Week High US$6.11 52 Week Low US$2.40 Beta 1.75 1 Month Change 15.54% 3 Month Change 66.67% 1 Year Change 19.70% 3 Year Change -5.83% 5 Year Change -24.67% Change since IPO -98.18%
Recent News & Updates Myomo, Inc. has completed a Follow-on Equity Offering in the amount of $15 million. Dec 06
Myomo, Inc. has filed a Follow-on Equity Offering. Dec 05
Third quarter 2024 earnings released: US$0.025 loss per share (vs US$0.058 loss in 3Q 2023) Nov 08 Myomo, Inc. Revises Revenue Guidance for the Year 2024
Myomo, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31
New minor risk - Financial position Aug 07 See more updates Myomo, Inc. has completed a Follow-on Equity Offering in the amount of $15 million. Dec 06
Myomo, Inc. has filed a Follow-on Equity Offering. Dec 05
Third quarter 2024 earnings released: US$0.025 loss per share (vs US$0.058 loss in 3Q 2023) Nov 08 Myomo, Inc. Revises Revenue Guidance for the Year 2024
Myomo, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31
New minor risk - Financial position Aug 07
Second quarter 2024 earnings released: US$0.03 loss per share (vs US$0.036 loss in 2Q 2023) Aug 07
Myomo, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 31
Myomo, Inc. Provides Revenue Guidance for the Second Quarter Ended June 30, 2024 Jul 08
Lead Independent Director recently bought €162k worth of stock Jun 03
Chief Medical Officer recently sold €120k worth of stock May 20
Forecast to breakeven in 2026 May 12
Myomo, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024 May 10
Full year 2023 earnings released: US$0.28 loss per share (vs US$1.52 loss in FY 2022) May 09
New minor risk - Profitability May 09
Myomo, Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
Myomo, Inc., Annual General Meeting, Jun 05, 2024 Apr 28
Myomo, Inc. Appoints Heather Getz as Class II Director and Chair of Audit Committee Mar 29
Lead Independent Director recently bought €161k worth of stock Mar 19
Forecast to breakeven in 2026 Mar 09
Myomo, Inc. Provides Earnings Guidance for the First Quarter of 2024 Mar 08
New minor risk - Market cap size Jan 26
Myomo, Inc. to Report Q4, 2023 Results on Mar 15, 2024 Jan 18 Myomo, Inc. has filed a Follow-on Equity Offering in the amount of $6.000002 million.
Forecast to breakeven in 2026 Dec 31
Third quarter 2023 earnings released: US$0.058 loss per share (vs US$0.40 loss in 3Q 2022) Nov 09
Myomo, Inc. Announces CMS Posts Proposed Medicare DMEPOS Fee Schedule Rate for the MyoPro for Review at the Upcoming HCPCS Public Meeting Nov 08
Myomo, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Nov 01
Chairman recently bought €56k worth of stock Sep 01
Second quarter 2023 earnings released: US$0.036 loss per share (vs US$0.42 loss in 2Q 2022) Aug 11
Myomo, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Aug 03
Centers for Medicare and Medicaid Services Accepts Myomo, Inc.'s Application to Classify the MyoPro as A Brace Jul 04
First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.41 loss in 1Q 2022) May 12
Myomo, Inc. Provides Revenue Guidance for the Second Quarter of 2023 May 11
Myomo, Inc. to Report Q1, 2023 Results on May 10, 2023 May 04
Full year 2022 earnings released: US$1.52 loss per share (vs US$1.89 loss in FY 2021) Mar 14
the National Disability Insurance Scheme in Australia Approves Myomo, Inc.'s MyoPro for Patient with Paralyzed Arm Feb 07
Myomo, Inc. Appoints Yitzchak Jacobovitz as A Class II Director Jan 31
Insufficient new directors Jan 01
Third quarter 2022 earnings released: US$0.40 loss per share (vs US$0.36 loss in 3Q 2021) Nov 16
Myomo, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022 and Full Year of 2023 Nov 11
Myomo, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 04
Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.47 loss in 2Q 2021) Aug 05
Myomo, Inc. Provides Revenue Guidance or Third Quarter 2022 Aug 04 Myomo, Inc. Provides Revenue Guidance for the Second Quarter of 202
First quarter 2022 earnings released: US$0.41 loss per share (vs US$0.57 loss in 1Q 2021) May 13
Myomo, Inc. to Report Q1, 2022 Results on May 11, 2022 May 05
Myomo, Inc., Annual General Meeting, Jun 08, 2022 May 02
No longer forecast to breakeven Apr 27
No longer forecast to breakeven Mar 11
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 11
Myomo, Inc. to Report Q4, 2021 Results on Mar 09, 2022 Mar 04
Myomo Announces MyoPro® 2+ Jan 07
Forecast to breakeven in 2024 Jan 01
Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.70 loss in 3Q 2020) Nov 12
Second quarter 2021 earnings released: US$0.47 loss per share (vs US$1.12 loss in 2Q 2020) Aug 12
No longer forecast to breakeven Jun 10
First quarter 2021 earnings released: US$0.57 loss per share (vs US$2.52 loss in 1Q 2020) May 09
Revenue beats expectations Mar 12
Full year 2020 earnings released: US$3.47 loss per share (vs US$19.35 loss in FY 2019) Mar 12
Myomo, Inc. to Report Q4, 2020 Results on Mar 10, 2021 Mar 05
Myomo, Inc. Announces Techniker Krankenkasse Approves Reimbursement of the Company Feb 17
New 90-day high: €12.10 Feb 13
Myomo® Forms Joint Venture to Manufacture and Sell the Company’s Products in China Jan 28
New 90-day high: €9.80 Jan 27
Myomo Inc.'s Sublease with Upstatement, LLC Becomes Effective Jan 21
New 90-day high: €7.50 Jan 12
Myomo, Inc. Introduces MyoGames Nov 17
Revenue beats expectations Nov 12
New 90-day high: €4.64 Nov 12
Third quarter 2020 earnings released: US$0.70 loss per share Nov 12
Myomo, Inc. to Report Q3, 2020 Results on Nov 10, 2020 Nov 05
Myomo, Inc. Appoints Harry Kovelman as Chief Medical Officer Nov 03
New 90-day low - €2.96 Aug 26
Earnings released Aug 11
Myomo, Inc. to Report Q2, 2020 Results on Aug 10, 2020 Aug 06
New 90-day low - €3.02 Jul 30 Shareholder Returns 0M61 DE Medical Equipment DE Market 7D 6.0% -0.5% -0.3% 1Y 19.7% -8.4% 7.0%
See full shareholder returns
Return vs Market: 0M61 exceeded the German Market which returned 7% over the past year.
Price Volatility Is 0M61's price volatile compared to industry and market? 0M61 volatility 0M61 Average Weekly Movement 10.1% Medical Equipment Industry Average Movement 6.6% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 0M61's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0M61's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Founded Employees CEO Website 2004 104 Paul Gudonis myomo.com
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living. It also provides the MyoPro 2, including control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+ that comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device.
Show more Myomo, Inc. Fundamentals Summary How do Myomo's earnings and revenue compare to its market cap? 0M61 fundamental statistics Market cap €186.57m Earnings (TTM ) -€8.06m Revenue (TTM ) €24.25m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0M61 income statement (TTM ) Revenue US$25.24m Cost of Revenue US$7.56m Gross Profit US$17.67m Other Expenses US$26.06m Earnings -US$8.38m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.28 Gross Margin 70.03% Net Profit Margin -33.22% Debt/Equity Ratio 0%
How did 0M61 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 07:50 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Myomo, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Benjamin Haynor Alliance Global Partners Scott Henry Alliance Global Partners Edward Woo Ascendiant Capital Markets LLC
Show 6 more analysts 
